NASDAQ:MDNA Medicenna Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $1.15 0.00 (0.00%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$1.14▼$1.2050-Day Range$0.79▼$1.3252-Week Range$0.76▼$3.05Volume5,246 shsAverage Volume95,418 shsMarket Capitalization$64.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Medicenna Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside653.6% Upside$8.67 Price TargetShort InterestHealthy0.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.61 out of 5 starsMedical Sector902nd out of 1,433 stocksPharmaceutical Preparations Industry447th out of 683 stocks 3.5 Analyst's Opinion Consensus RatingMedicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.67, Medicenna Therapeutics has a forecasted upside of 653.6% from its current price of $1.15.Amount of Analyst CoverageMedicenna Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.35% of the float of Medicenna Therapeutics has been sold short.Short Interest Ratio / Days to CoverMedicenna Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medicenna Therapeutics has recently decreased by 36.36%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedicenna Therapeutics does not currently pay a dividend.Dividend GrowthMedicenna Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDNA. Previous Next 2.8 News and Social Media Coverage News SentimentMedicenna Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Medicenna Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for MDNA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Medicenna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 7.98% of the stock of Medicenna Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medicenna Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medicenna Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Medicenna Therapeutics (NASDAQ:MDNA) StockMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More MDNA Stock News HeadlinesJuly 3, 2022 | benzinga.comEncouraging CD8+ T Cell and NK Cell Responses in ABILITY TrialJuly 2, 2022 | americanbankingnews.comMedicenna Therapeutics Corp. to Post Q2 2023 Earnings of ($0.08) Per Share, Zacks Small Cap Forecasts (NASDAQ:MDNA)June 29, 2022 | americanbankingnews.comAnalysts Issue Forecasts for Medicenna Therapeutics Corp.'s Q1 2023 Earnings (NASDAQ:MDNA)June 27, 2022 | finance.yahoo.comMDNA: Encouraging CD8+ T Cell and NK Cell Responses in ABILITY Trial…June 27, 2022 | americanbankingnews.comOppenheimer Research Analysts Boost Earnings Estimates for Medicenna Therapeutics Corp. (NASDAQ:MDNA)June 26, 2022 | americanbankingnews.comResearch Analysts Set Expectations for Medicenna Therapeutics Corp.'s FY2027 Earnings (NASDAQ:MDNA)June 25, 2022 | finance.yahoo.comMarket Sentiment Around Loss-Making Medicenna Therapeutics Corp. (TSE:MDNA)June 25, 2022 | americanbankingnews.comMedicenna Therapeutics (NASDAQ:MDNA) Stock Rating Reaffirmed by HC WainwrightJune 24, 2022 | americanbankingnews.comMedicenna Therapeutics (NASDAQ:MDNA) PT Lowered to $10.00June 22, 2022 | seekingalpha.comMedicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call TranscriptJune 22, 2022 | finance.yahoo.comMedicenna Reports Fiscal Year 2022 Financial Results and Operational HighlightsJune 21, 2022 | americanbankingnews.comMedicenna Therapeutics (MDNA) Set to Announce Earnings on WednesdayJune 20, 2022 | americanbankingnews.comMedicenna Therapeutics (MDNA) Scheduled to Post Earnings on WednesdayJune 7, 2022 | finance.yahoo.comMedicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022May 11, 2022 | benzinga.comMedicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy MeetingMay 11, 2022 | finance.yahoo.comMedicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy MeetingMay 2, 2022 | finance.yahoo.comMedicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY StudyApril 10, 2022 | seekingalpha.comMedAvail, Lyra Therapeutics top healthcare gainers; BioCryst, Sunshine Biopharma lead loser's packApril 8, 2022 | finance.yahoo.comMedicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual MeetingMarch 10, 2022 | finance.yahoo.comMedicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferenceFebruary 15, 2022 | finance.yahoo.comMDNA: Encouraging Early Clinical Data from ABILITY Study…February 9, 2022 | finance.yahoo.comMedicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational HighlightsFebruary 2, 2022 | finance.yahoo.comMedicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022January 31, 2022 | finance.yahoo.comMedicenna Announces Formation of its Scientific Advisory BoardDecember 22, 2021 | finance.yahoo.comMedicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY StudySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDNA CUSIPN/A CIK1807983 Webwww.medicenna.com Phone(416) 648-5555Fax416-572-7501Employees13Year FoundedN/ACompany Calendar Last Earnings6/22/2022Today7/07/2022Next Earnings (Estimated)8/12/2022Fiscal Year End3/31/2023Price Target and Rating Average Stock Price Forecast$8.67 High Stock Price Forecast$11.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+595.7%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares56,304,000Free FloatN/AMarket Cap$64.75 million OptionableNot Optionable Beta0.88 Medicenna Therapeutics Frequently Asked Questions Should I buy or sell Medicenna Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock. View analyst ratings for Medicenna Therapeutics or view top-rated stocks. What is Medicenna Therapeutics' stock price forecast for 2022? 3 Wall Street research analysts have issued 12 month price targets for Medicenna Therapeutics' shares. Their MDNA stock forecasts range from $5.00 to $11.00. On average, they predict Medicenna Therapeutics' share price to reach $8.67 in the next year. This suggests a possible upside of 653.6% from the stock's current price. View analysts' price targets for Medicenna Therapeutics or view top-rated stocks among Wall Street analysts. How has Medicenna Therapeutics' stock price performed in 2022? Medicenna Therapeutics' stock was trading at $1.63 at the beginning of the year. Since then, MDNA stock has decreased by 29.4% and is now trading at $1.15. View the best growth stocks for 2022 here. When is Medicenna Therapeutics' next earnings date? Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Medicenna Therapeutics. How were Medicenna Therapeutics' earnings last quarter? Medicenna Therapeutics Corp. (NASDAQ:MDNA) released its quarterly earnings data on Wednesday, June, 22nd. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. View Medicenna Therapeutics' earnings history. Who are Medicenna Therapeutics' key executives? Medicenna Therapeutics' management team includes the following people: Dr. Fahar Merchant Ph.D., Founder, Chairman, Pres & CEO (Age 65, Pay $358.54k)Ms. Rosemina Merchant B.Sc., M.E.Sc, Founder, Chief Devel. Officer & Director (Age 65, Pay $287.52k)Ms. Elizabeth Williams C.A., CPA, CA, CPA, CFO & Corp. Sec. (Age 44, Pay $241.27k)Dr. Martin Bexon M.D., MBBS, Acting Chief Medical Officer & Head of Clinical Devel.Dr. Samuel R. Denmeade M.D., Scientific Advisor Who are some of Medicenna Therapeutics' key competitors? Some companies that are related to Medicenna Therapeutics include Rallybio (RLYB), Verona Pharma (VRNA), G1 Therapeutics (GTHX), Provention Bio (PRVB), CymaBay Therapeutics (CBAY), Theseus Pharmaceuticals (THRX), XOMA (XOMA), InterCure (INCR), Inventiva (IVA), Zomedica (ZOM), Epizyme (EPZM), Thorne HealthTech (THRN), KalVista Pharmaceuticals (KALV), AVEO Pharmaceuticals (AVEO) and Viking Therapeutics (VKTX). View all of MDNA's competitors. What is Medicenna Therapeutics' stock symbol? Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA." How do I buy shares of Medicenna Therapeutics? Shares of MDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Medicenna Therapeutics' stock price today? One share of MDNA stock can currently be purchased for approximately $1.15. How much money does Medicenna Therapeutics make? Medicenna Therapeutics (NASDAQ:MDNA) has a market capitalization of $64.75 million. The company earns $-18,010,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. How many employees does Medicenna Therapeutics have? Medicenna Therapeutics employs 13 workers across the globe. How can I contact Medicenna Therapeutics? Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The official website for Medicenna Therapeutics is www.medicenna.com. The company can be reached via phone at (416) 648-5555, via email at ir@medicenna.com, or via fax at 416-572-7501. This page (NASDAQ:MDNA) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
